This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146: 87–95.
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645–1654.
Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101: 317–324.
Leung AY, Chim CS, Ho PL, Cheng VC, Yuen KY, Lie AK et al. Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 2002; 50: 316–319.
Gruber SA, Doshi MD, Cincotta E, Brown KL, Singh A, Morawski K et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation 2008; 86: 269–274.
Serrano D, Miralles P, Balsalobre P, Diez-Martin JL, Berenguer J . Hematopoietic stem cell transplantation in patients infected with HIV. Curr HIV/AIDS Rep 2010; 7: 175–184.
Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355–365.
Hutter G, Zaia JA . Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol 2011; 163: 284–295.
Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31: 139–152.
Bickel M, Anadol E, Vogel M, Hofmann WP, von Hentig N, Kuetscher J et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010; 65: 999–1004.
Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc 2002; 34: 1540–1541.
Marfo K, Greenstein S . Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc 2009; 41: 3796–3799.
Morelle J, Goffin E, Wallemacq P, De Meyer M, Yombi JC, Mourad M et al. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended!. Transpl Int 2010; 23: 1065–1067.
Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 864–871.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miceli, M., Cronin, S., Ayash, L. et al. Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient. Bone Marrow Transplant 47, 1140–1142 (2012). https://doi.org/10.1038/bmt.2011.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.230